Novartis Cements Chiron Buy With Increased Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron shareholders have agreed to vote in favor of the takeover at $48 per share, up from $45 per share deal Chiron accepted in October.
You may also be interested in...
Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.